Digoxin and Vibegron interaction
Digoxin and Vibegron: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Digoxin label · effective 2025-04-10
Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias.
From the Vibegron (GEMTESA) label · effective 2025-04-01
Concomitant use of GEMTESA increases digoxin maximal concentrations (C max ) and systemic exposure as assessed by area under the concentration-time curve (AUC) [see Clinical Pharmacology ( 12.3 )] .
Serum digoxin concentrations should be monitored before initiating and during therapy with GEMTESA and used for titration of the digoxin dose to obtain the desired clinical effect.
Continue monitoring digoxin concentrations upon discontinuation of GEMTESA and adjust digoxin dose as needed.
Monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect.
Digoxin : Measure serum digoxin concentrations before initiating GEMTESA.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.